The FDA hasn’t been transparent and open enough with how it has implemented the Commissioner’s National Priority Voucher program, patient, industry and trade groups said Thursday. Several ...

Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to ...

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

Alnylam Pharmaceuticals is linking up with Inceptive Nucleics in a deal that aligns with the growing biopharma trend of using generative AI to aid drug development. The Massachusetts biotech is ...

With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs. Eli Lilly and ...

All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met. Regeneron continues its deal streak with an expanded ...

It’s not unusual for it to take unemployed biopharma professionals awhile to land new jobs. Three experts discuss when employment gaps are an issue and how to explain them to prospective employers.

Erik Paulsen is the chairman of the Institute for Gene Therapies and a former Member of Congress (MN-3), serving from 2009 to ...

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast ...

Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China ...

Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher ...